Surgical Resection of Pulmonary Metastasis from Renal Cell Carcinoma by Kim, Jae Jun et al.
Korean J Thorac Cardiovasc Surg 2011;44:159-164 □ Clinical Research □
DOI:10.5090/kjtcs.2011.44.2.159 ISSN: 2233-601X (Print)   ISSN: 2093-6516 (Online)
− 159  −
*Department  of  Thoracic  and  Cardiovascular  Surgery,  College  of  Medicine,  The  Catholic  University  of  Korea
Received:  August  18,  2010,  Revised:  December  30,  2010,  Accepted:  February  8,  2011
Corresponding  author: Jae-Kil  Park,  Department  of  Thoracic  and  Cardiovascular  Surgery,  St.  Mary’s  Hospital,  Catholic  Cancer  Center,  505, 
Banpo-dong,  Seocho-gu,  Seoul  137-040,  Korea
(Tel)  82-2-2258-2858  (Fax)  82-2-594-8644  (E-mail)  jaekpark@catholic.ac.kr
 C  The  Korean  Society  for  Thoracic  and  Cardiovascular  Surgery.  2011.  All  right  reserved.
CC  This  is  an  open  access  article  distributed  under  the  terms  of  the  Creative  Commons  Attribution  Non-Commercial  License  (http://creative-
commons.org/licenses/by-nc/3.0)  which  permits  unrestricted  non-commercial  use,  distribution,  and  reproduction  in  any  medium,  provided  the 
original  work  is  properly  cited.
Surgical Resection of Pulmonary Metastasis 
from Renal Cell Carcinoma
Jae  Jun  Kim,  M.D.*,  Jae-Kil  Park,  M.D.*,  Young-Pil  Wang,  M.D.*
Background:  Renal cell carcinoma has shown less response to systemic therapies including chemotherapy, radia-
tion, and immunotherapy than other cancers. Surgery has therefore become an important treatment tool. The proto-
col for treatment is the same for pulmonary metastasis of renal cell carcinoma. We performed surgery for pulmo-
nary metastatic renal cell carcinomas and analyzed the results. Materials and Methods: We retrospectively ana-
lyzed 15 patients who had undergone pulmonary metastasectomy from renal cell carcinoma at our hospital from 
January 2005 to December 2009. Results: No patients had extrathoracic metastatsis. The mean age was 60.2 
years (range 35∼73). There were 12 male and 3 female patients. The number of synchronous and metachronous 
patients were 8 and 7, respectively. The mean survival times of synchronous and metachronous patients were 32.6 
and 42.9 months, respectively. 6 patients had single lesions and 9 patients had multiple (more than 3) lesions. 
The surgical procedures included wedge resection (10), lobectomy (2), wedge resection with segmentectomy (2), 
and segmentectomy (1). Median observation and survival time were 54.1 and 34.9 months. The 1-year and 3-year 
survival rates were 80% and 50%, respectively. Conclusion: Pulmonary resection for pulmonary metastatic renal 
cell carcinoma was found to be a safe and effective treatment modality when complete resection was performed.
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INTRODUCTION
Many studies have been published on the effects of pulmo-
nary  metastatectomy  [1,2].  Because  effective  chemotherapy, 
radiation,  and  biologic  therapies  have  not  been  introduced  to 
date,  surgical  treatments  seem  to  represent  the  most  effective 
treatment.  Renal  cell  carcinoma  accounts  for  about  2%  of  all 
cancers  [3,4].  The  lungs  are  the  most  frequent  site  for  meta-
stases, and nearly 20% of all patients with renal cell carcino-
ma  have  pulmonary  metastases  when  they  are  first  diagnosed 
[3,5-8].  The  prognosis  for  patients  with  unresected  metastatic 
renal  cell  cancer  is  very  poor.  The  mean  survival  time  is 
from  6  to  10  months  and  the  5-year  survival  rates  reported 
range  from  5%  to  10%  [3,4,8,9].  The  complete  resection  of 
metastatic  lesions  offers  markedly  improved  survival  rates  [4, 
5].  The  role  of  pulmonary  metastatectomy  still  represents  a 
widely  debated  issue  due  to  the  introduction  of  new  im-
munotherapies  and  biologic  therapies  [10].  A  retrospective 
analysis of patients with pulmonary metastases from renal cell 
carcinomas  was  performed  to  show  the  effects  of  pulmonary 
metastectomy.Jae Jun Kim, et al
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Table 1. Patients’ characteristics
Gender
    Male 12  patients
    Female   3  patients
Nephrectomy
  R i g h t  6  p a t i e n t s
    Left   9  patients
Stage  of  renal  cell  carcinoma
  I  3  p a t i e n t s
    II   3  patients
  I I I 1  p a t i e n t
    IV   8  patients
Disease-free  interval
    Metachronous  7  patients 58.4  months  (24∼144  months)
Laterality
    Unilateral  lesions   8  patients
    Bilateral  lesions   7  patients
Number  of  tumors
    Single  lesion   6  patients
  M u l t i p l e  l e s i o n s  ( m o r e  t h a n  3 )  9  p a t i e n t s
Size  of  tumor
  S i n g l e  l e s i o n 1 5 . 8  m m  ( 7 . 3 ∼34.1  mm)
    Multiple  lesions(  largest  one) 14.8  mm  (7.2∼33.9  mm)
Performance  (ECOG)
    Single  lesion 0.83  (0∼2)
    Multiple  lesions 0.77  (0∼1)
Surgical  procedure
    Wedge  resection 10  patients
    Segmentectomy 1  patient
    Lobectomy   2  patients
    Segmentectomy  and  lobectomy   2  patients
Survival  time
    Complete  resection 45.6  months  (24∼60  months)
    Incomplete  resection 25.2  months  (13∼42  months)
Systemic  therapy
    Before  metastasectomy   3  patients
    After  metastasectomy   7  patients
Completeness  of  resection
    Complete  resection   7  patients
    Incomplete  resection   8  patients
MATERIALS AND METHODS
    From  January  2005  to  December  2009,  15  patients  under-
went  pulmonary  resection  of  renal  cell  carcinoma  metasta-
sized  to  the  lung  at  our  cancer  center.  Medical  records  were 
retrospectively  reviewed.
    All  patients  who  underwent  resection  of  their  pulmonary 
m e t a s t a s e s  m e t  t h e  f o l l o w i n g  c r i t e r i a :  ( 1 )  p u l m o n a r y  l e s i o n s  
were deemed resectable by not only the radiological examina-
tions  but  also  by  the  patients’  general  conditions,  (2)  meta-
static disease was limited to the thorax,  (3)  locoregional  con-
trol of their primary renal lesions was obtained or obtainable, 
and (4) metastatectomy was performed for complete resection 
or  for  pathologic  diagnosis  for  further  treatment  plans.
    All  patients  were  retrospectively  analyzed  for  gender,  age, 
systemic  therapy,  disease-free  interval,  type  of  pulmonary  re-
sections, number of  pulmonary  metastases, stage of  renal cell 
carcinoma,  and  completeness  of  resection.  Disease-free  inter-
val  was  defined  as  the  time  between  nephrectomy  and  meta-
stasectomy in metachronous patients. Actuarial survival curves 
w e r e  e s t i m a t e d  u s i n g  t h e  K a p l a n-Meier  method.  Statistical 
comparisons  among  prognostic  factors  were  made  using  the 
log-rank test. Because of the  small number of cases, a p-val-
ue  less  than  0.1  was  considered  statistically  significant. 
RESULTS
    15  patients  with  pulmonary  metastases  from  renal  cell  car-
cinoma  underwent  pulmonary  resections  (Table  1).  The  me-
d i a n  a g e  w a s  6 0 . 2  y e a r s ,  w i t h  a  r a n g e  o f  3 5 ∼7 3  y e a r s .  1 2  
patients  were  male  and  3  patients  were  female,  and  the  sex 
ratio was 4：1. There were 3 cases of stage I renal cell car-
cinoma,  3  cases  of  stage  II,  1  case  of  stage  III,  and  8  cases 
of  stage  IV.  10  patients  underwent  wedge  resections  (includ-
ing  both  sided),  2  patients  underwent  lobectomy,  2  patients 
underwent  segmentectomy  with w e d g e  r e s e c t i o n ,  a n d  1  p a -
tient underwent segmentectomy. Median observation time was 
54.1  months.  9  patients  died  during  observation  and  6  pa-
tients  died  of  progressive  renal  cell  carcinoma.  Median  sur-
vival  time  was  34.9  months.  The  1-year  and  3-year  survival 
rates  were  80%  and  50%,  respectively  (Fig.  1).  The  median 
survival  time  of  male  a n d  f e m a l e  p a t i e n t s  w a s  3 5 . 0  a n d  3 7 . 0  
months,  and  there  were  no  significant  differences  between 
genders  (p-value  0.821).  7  patients  underwent  complete  re-
section of the pulmonary metastases and 8 patients underwent 
i n c o m p l e t e  r e s e c t i o n ,  d u e  t o  m o r e  l e s i o n s  b e i n g  f o u n d  t h a n  
were  known  during  preoperative  evaluation  and  the  need  for 
pathological  confirmation  to  further  plan  treatment.  The  me-
dian  survival  time  in  patients  with  incomplete  resections  was 
25.2  months  compared  with  45.6  months  in  patients  with Pulmonary Metastasis from Renal Cell Carcinoma
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Fig. 1. Overall survival time was 34.9 months. The 1-year and 3- 
year survival rates were 80% and 50%, respectively.
Fig. 2. Completeness of resection (C=Complete resection; I= 
Incomplete resection). Complete resections provided longer-term 
survival than incomplete ones (45.6 vs 25.2 months). 
Fig. 3. Systemic therapy (Before=Systemic therapy before pulmonary resection; After=Systemic therapy after pulmonary resection; Y=With 
systemic therapy; N:=Without systemic therapy). Systemic therapy after pulmonary resection provided a statistically different survival but, par-
adoxically, receiving systemic therapy provided shorter survival than not doing so.
complete resections, which constituted a significant difference 
(p-value 0.069)(Fig. 2). Pulmonary metastases were diagnosed 
synchronously in 8 patients and metachronously in 7 patients. 
The median survival time was 42.9 months  for metachronous 
patients  versus  32.6  months  for  synchronous  patients.  There 
was no significant difference between the two groups (p-value 
0.660).  6  patients  had  a  single  lung  metastasis  and  9  had 
more than three metastases, the median survival was 43.7 and 
26.6  months  respectively  and  there  was  no  significant  differ-
ence between the two groups (p-value 0.128). Only 3 patients 
received systemic therapy (IL-2, INF-a) after the nephrectomy 
and  before  the  pulmonary  metast a s e c t o m y ,  a n d  7  p a t i e n t s  r e -
ceived  systemic  therapy  (IL-2,  INF-a,  5-FU)  after  pulmonary 
metastasectomy.  Systemic  therapy  before  pulmonary  resection 
provided no statistically significant survival improvement, sys-
temic  therapy  after  pulmonary  resection  resulted  in  a  statisti-
cally  significant  difference  in  survival,  but,  paradoxically,  re-
ceiving  systemic  therapy  resulted  in  shorter  survival  than  no 
therapy  (p-value  0.055)(Fig.  3).  There  was  no  significant  dif-
ference for the stage of primary renal cell carcinoma (p-value Jae Jun Kim, et al
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0.482).  There  were  2  complete r e s e c t i o n  p a t i e n t s  a n d  2  i n -
complete  resection  patients  who  were  suspected  of  having 
metastatic  mediastinal  lymph  nodes  before  pulmonary  meta-
statectomy,  but  dissections  of  the  nodes  were  not  performed. 
After  pulmonary  metastasectomy,  recurrence  in  the  lung  de-
veloped  in  2  of  7  complete  resection  patients.  Metastases  to 
other  organs  were  found  in  10  patients,  including  the  media-
s t i n a l  l y m p h  n o d e s  f o r  6  p a t i e n t s ,  b o n e s  f o r  5 ,  l i v e r  f o r  3 ,  
and  the  brain  for  2.  A  single  metastasis  occurred  in  4  of  the 
patients and multiple organ metastases occurred in 6 patients. 
DISCUSSION
    Many  studies  have  been  conducted  on  pulmonary  meta-
stasectomy,  and  it  has  become  the  standard  therapy  for  vari-
ous  metastatic  solid  malignancies  to  the  lungs  [2,4,5,11-14]. 
Metastases  of  primary  tumors  that  do  not  respond  well  to 
chemotherapy,  radiotherapy,  or  a  combination  of  both  thera-
pies  are  especially  well  suited  for  surgical  resection.  One 
third  of  patients  with  renal  cell  carcinoma  present  with  syn-
chronous  pulmonary  metastases,  and  of  the  remainder,  50% 
ultimately  develop  pulmonary  metastases  [2].  The  lung  is  the 
most  frequently  affected  metastatic  site  in  patients  with  renal 
cell carcinoma [4-6,10,11]. The prognosis of patients with un-
resected  metastatic  renal  cell  cancer  is  very  poor,  the  mean 
survival time is from 6 to 10 months and the 5-year survival 
rates  reported  range  from  5  to  10%  [5,9,13].  The  patients 
with renal cell carcinoma can benefit from systemic therapies 
including  cytokines  and  immunotherapy,  but  the  effects  of 
systemic therapies on pulmonary metastasis are small, achiev-
ing  responses  in  15%  to  35%  of  these  patients  [1,3,9,11,13]. 
The  first  resection  of  a  pulmonary  metastasis  in  a  patient 
with  renal  cell  carcinoma  was  performed  by  Barney  and 
Churchill  in  1939.  Since  then,  surgery  remains  the  safe  and 
effective  treatment  for  patients  with  pulmonary  metastases 
[1-3,5,11,15].  Most  pulmonary  metastases  are  located  periph-
erally and are frequently immediately subpleural, amenable to 
a wedge resection. It appears that wedge resection, if feasible, 
is as effective as anatomic resection [14]. If there is no other 
metastatic  lesion  and  complete  resection  is  possible,  meta-
stasectomy  should  be  considered f o r  l o n g e r  s u r v i v a l  [ 1 1 ] .  
    According to the studies, the most important determinant of 
survival  was  resectability.  The  overall  5-year  survival  for  pa-
tients  who  underwent  complete  resection  was  36%,  with  a 
median survival of 35 months. In those patients who had un-
dergone incomplete resection, the 5-year survival rate was on-
ly  13%,  and  the  median  survival  was  15  months  [6,11].  In 
our  study,  the  median  survival  time  in  patients  with  in-
complete  resections  was  25.2  months,  compared  with  45.6 
months  for  patients  with  complete  resections.  There  was  a 
significant  differenc e  b e t w e e n  t h e  t w o  g r o u p s .  F u t u r e  s t u d i e s  
could  investigate  preoperative  assessments  and  the  possibility 
of  complete  resection  with  an  adequate  pulmonary  reserve, 
including  an  appraisal  of  the  number  of  nodules,  consid-
eration of  the location  of nodules, and an evaluation  of post-
operative  pulmonary  function  [2,11].  The  computed  tomo-
graphic  (CT)  scan  and  PET-CT  of  the  chest  are  regarded  as 
the  most  important  preoperative  examinations,  and  we  also 
referred  to  the  chest  CT  and  PET-CT  for  complete  resection. 
Functional  loss  after  three  or  more  non-anatomical  resections 
is  comparable  with  that  observed  for  lobectomy  [16]. 
    According  to  multiple  studies,  a  long  disease-free  interval 
(DFI)  is  considered  a  favorable  prognostic  factor  in  cases  of 
pulmonary metastasis. One study reported that patients with a 
DFI  of  48  months  or  more  achieved  a  5-year  survival  of 
46%, compared to 26% for those with a DFI of less than 48 
months  [5],  and  another  study  reported  the  5-year  survival 
rate  in  patients  with  a  DFI  of  more  than  23  months  was 
47%, compared to 24.7% in patients with a DFI of 23 months 
or  less  [2-5,13,17].  Longer  DFI  does  not  always  imply  slow 
tumor  growth  or  the  absence  of o t h e r  m e t a s t a s e s .  O n e  s t u d y  
reported  that  late  renal  cell  carcinoma  metastases  are  often 
combined  with  rapid  disease  progression  [13],  and  there  was 
no survival difference between synchronous and metachronous 
patients  in  our  study.  The  median  DFI  of  metachronous  pa-
tients was 58.4 months. The survival of the metachronous pa-
tients by DFI could not be estimated due to the small number 
of  cases. 
    The number of metastatic lesions discovered before or dur-
ing  operation  has  been  studied.  Some  studies  have  reported 
that the number of metastases was highly significant and that 
patients  with  single  metastases  had  a  survival  of  43%  at  5 
years,  compared  with  34%  for  those  with  two  or  three  meta-
s t a s e s ,  a n d  2 7 %  f o r  t h o s e  w i t h  f o u r  o r  m o r e  m e t a s t a s e s ,  b u t  Pulmonary Metastasis from Renal Cell Carcinoma
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other  studies  reported  that  the  number  of  metastases  was  not 
an  important  factor  [5,10,14,18].  Univariate  analysis  of  our 
data  shows  that  the  number  of  metastases  is  not  a  relevant 
prognostic factor. The indication for operation cannot be based 
only on the number of metastatic lesions, since some patients 
with  multiple  metastatic  lesions  show  longer  than  5-year 
survival.  The  greater  the  number  of  pulmonary  nodules  iden-
tified by preoperative chest CT in combination with renal dis-
ease,  the  higher  the  probability  of  incomplete  resection  [15]. 
Pulmonary  metastasis  with  incomplete  resection  has  a  longer 
survival  than  unresected  pulmonary  metastasis.  This  shows 
that  incomplete  resection  can  attenuate  the  tumor  burden  and 
can potentiate the immune system and the effects of systemic 
therapy  [11].
    The  role of metastasectomy for  renal cell carcinoma in the 
era  of  emerging  effective  systemic  therapy  (usually  immuno-
therapy)  has  not  yet  been  defined,  except  for  solitary  metas-
tasis.  In  order  to  achieve  complete  eradication  of  metastatic 
disease,  we  propose  these  guidelines  [11].  First,  we  would 
encourage  aggressive  surgical  resection  of  the  clinically  soli-
tary  metastasis,  whether  synchronous  or  metachronous. 
Continued  follow-up  of  those  patients  may  be  necessary  in-
definitely,  because  relapse  is  quite  likely,  but  adjuvant  sys-
temic  therapy  should  not  be  initiated  unless  it  is  within 
protocol.  Second,  limited  metastases  in  only  one  organ  may 
behave similarly to a solitary metastasis, and if the metastases 
are  in  a  site  amenable  to  surgical  resection,  e.g.,  lung,  initial 
surgery  might  be  reasonable.  Systemic  therapy  for  these  pa-
tients  is  highly  recommended  and  need  not  necessarily  wait 
for  recurrence.  Third,  for  patients  with  multiple  metastases, 
initial  systemic therapy  followed then  by resection  of any re-
sidual  disease  in  selected  patients  seems  to  be  supported  by 
the  experience  at  several  medical  centers.
    There  are  several  limitations  to  our  analysis.  The  biggest 
limitation  is  the  number  of  cases.  Since  the  number  of  pa-
t i e n t s  f o r  p u l m o n a r y  m e t a s t a s ectomy  of  renal  cell  carcinoma 
was  so  small  in  our  institution, i t  w o u l d  b e  d i f f i c u l t  t o  d e -
termine a certain decision. A large-scale prospective study in-
volving  multiple  institutions  is  necessary. 
    Because  pulmonary  metastasectomy  for  renal  cell  carcino-
ma  is  safe,  survival  depends  on  a  complete  resection  of  pul-
monary  disease  and  an  adequate  pulmonary  reserve.
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